{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:47:25Z","timestamp":1786985245365,"version":"build-2736575974"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T00:00:00Z","timestamp":1695772800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["21S11902000"],"award-info":[{"award-number":["21S11902000"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019534","name":"Science Fund for Distinguished Young Scholars of Guangxi Province","doi-asserted-by":"publisher","award":["2021JJ10073"],"award-info":[{"award-number":["2021JJ10073"]}],"id":[{"id":"10.13039\/501100019534","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.biopha.2023.115611","type":"journal-article","created":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T08:06:33Z","timestamp":1695974793000},"page":"115611","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Discovery of WD-890: A novel allosteric TYK2 inhibitor for the treatment of multiple autoimmune diseases"],"prefix":"10.1016","volume":"167","author":[{"given":"Zhiqin","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenliang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6964-7131","authenticated-orcid":false,"given":"Mingzhu","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.biopha.2023.115611_bib1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.autrev.2017.11.010","article-title":"Physical activity and autoimmune diseases: Get moving and manage the disease","volume":"17","author":"Sharif","year":"2018","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.biopha.2023.115611_bib2","doi-asserted-by":"crossref","unstructured":"Crow M.K., Olferiev M., Kirou K.A. Type I Interferons in Autoimmune Disease. In: Abbas A.K., Aster J.C., Feany M.B., editors. Annual Review of Pathology: Mechanisms of Disease, Vol 14. Annual Review of Pathology-Mechanisms of Disease. 142019. p. 369\u2013393.","DOI":"10.1146\/annurev-pathol-020117-043952"},{"issue":"3","key":"10.1016\/j.biopha.2023.115611_bib3","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.yfrne.2014.04.004","article-title":"Gender differences in autoimmune disease","volume":"35","author":"Ngo","year":"2014","journal-title":"Front. Neuroendocrinol."},{"issue":"4","key":"10.1016\/j.biopha.2023.115611_bib4","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/joim.12395","article-title":"Human autoimmune diseases: a comprehensive update","volume":"278","author":"Wang","year":"2015","journal-title":"J. Intern. Med."},{"issue":"3","key":"10.1016\/j.biopha.2023.115611_bib5","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","article-title":"The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis","volume":"55","author":"Blauvelt","year":"2018","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"4","key":"10.1016\/j.biopha.2023.115611_bib6","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.gpb.2015.04.002","article-title":"Biomarkers of an autoimmune skin disease-psoriasis","volume":"13","author":"Jiang","year":"2015","journal-title":"Genom. Proteom. Bioinforma."},{"issue":"19","key":"10.1016\/j.biopha.2023.115611_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27196640","article-title":"S100 proteins as novel therapeutic targets in psoriasis and other autoimmune diseases","volume":"27","author":"Kurpet","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2023.115611_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coi.2017.07.007","article-title":"Psoriasis: a mixed autoimmune and autoinflammatory disease","volume":"49","author":"Liang","year":"2017","journal-title":"Curr. Opin. Immunol."},{"issue":"3","key":"10.1016\/j.biopha.2023.115611_bib9","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2009.02.015","article-title":"The burden of autoimmune disease: a comparison of prevalence ratios in patients with psoriatic arthritis and psoriasis","volume":"61","author":"Makredes","year":"2009","journal-title":"J. Am. Acad. Dermatol."},{"issue":"7","key":"10.1016\/j.biopha.2023.115611_bib10","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1111\/j.1572-0241.2007.01215.x","article-title":"Clustering of inflammatory bowel disease with immune mediated diseases among members of a northern california-managed care organization","volume":"102","author":"Weng","year":"2007","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.biopha.2023.115611_bib11","article-title":"Psoriasis","volume":"2","author":"Greb","year":"2016","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.biopha.2023.115611_bib12","doi-asserted-by":"crossref","DOI":"10.1186\/s41232-020-00133-8","article-title":"Rheumatoid arthritis","volume":"40","author":"Tanaka","year":"2020","journal-title":"Inflamm. Regen."},{"issue":"9894","key":"10.1016\/j.biopha.2023.115611_bib13","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(13)60954-X","article-title":"Autoimmune rheumatic diseases 3 immunopathogenic mechanisms of systemic autoimmune disease","volume":"382","author":"Wahren-Herlenius","year":"2013","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.biopha.2023.115611_bib14","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/ar1966","article-title":"Aspects of early arthritis. Traditional DMARD therapy: is it sufficient?","volume":"8","author":"Machold","year":"2006","journal-title":"Arthritis Res. Ther."},{"issue":"12","key":"10.1016\/j.biopha.2023.115611_bib15","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.autrev.2010.07.018","article-title":"The effect of pharmacological therapy on the cardiovascular system of patients with systemic rheumatic diseases","volume":"9","author":"Atzeni","year":"2010","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.biopha.2023.115611_bib16","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.biopha.2016.02.001","article-title":"Advancement in contemporary diagnostic and therapeutic approaches for rheumatoid arthritis","volume":"79","author":"Kumar","year":"2016","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2023.115611_bib17","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.bcp.2019.04.009","article-title":"Risks and benefits of corticosteroids in arthritic diseases in the clinic","volume":"165","author":"Petta","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.biopha.2023.115611_bib18","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.biopha.2018.07.027","article-title":"Novel drug delivery systems for NSAIDs in management of rheumatoid arthritis: an overview","volume":"106","author":"Thakur","year":"2018","journal-title":"Biomed. Pharmacother."},{"issue":"2","key":"10.1016\/j.biopha.2023.115611_bib19","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1136\/annrheumdis-2017-211555","article-title":"Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?","volume":"77","author":"Baker","year":"2018","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.biopha.2023.115611_bib20","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus secukinumab in plaque psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"New Engl. J. Med."},{"issue":"1","key":"10.1016\/j.biopha.2023.115611_bib21","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/BOR.0b013e32835b1366","article-title":"Biologics-induced autoimmune diseases","volume":"25","author":"Perez-Alvarez","year":"2013","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.biopha.2023.115611_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2017.00460","article-title":"Drugs for autoimmune inflammatory diseases: from small molecule compounds to Anti-TNF biologics","volume":"8","author":"Li","year":"2017","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.biopha.2023.115611_bib23","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00011-020-01339-9","article-title":"Interleukin 23 and autoimmune diseases: current and possible future therapies","volume":"69","author":"Abdo","year":"2020","journal-title":"Inflamm. Res."},{"issue":"3","key":"10.1016\/j.biopha.2023.115611_bib24","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1517\/17425247.2015.972931","article-title":"Targeted delivery systems for biological therapies of inflammatory diseases","volume":"12","author":"Tran","year":"2015","journal-title":"Expert Opin. Drug Deliv."},{"issue":"4","key":"10.1016\/j.biopha.2023.115611_bib25","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/01.mog.0000231810.87901.e8","article-title":"Safety issues with biological therapies for inflammatory bowel disease","volume":"22","author":"Van Assche","year":"2006","journal-title":"Curr. Opin. Gastroenterol."},{"issue":"7","key":"10.1016\/j.biopha.2023.115611_bib26","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1080\/14740338.2017.1338273","article-title":"A safety assessment of biological therapies targeting the IL-23\/IL-17 axis in inflammatory bowel diseases","volume":"16","author":"Verstockt","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"issue":"5","key":"10.1016\/j.biopha.2023.115611_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22052719","article-title":"The role of tumor necrosis factor alpha (TNF-alpha) in autoimmune disease and current TNF-alpha inhibitors in therapeutics","volume":"22","author":"Jang","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.biopha.2023.115611_bib28","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s00281-019-00733-8","article-title":"The pathogenicity of Th17 cells in autoimmune diseases","volume":"41","author":"Yasuda","year":"2019","journal-title":"Semin. Immunopathol."},{"issue":"5","key":"10.1016\/j.biopha.2023.115611_bib29","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.biopha.2023.115611_bib30","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","article-title":"Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases","volume":"12","author":"Schwartz","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.biopha.2023.115611_bib31","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.phrs.2016.07.038","article-title":"Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases","volume":"111","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"issue":"7128","key":"10.1016\/j.biopha.2023.115611_bib32","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nature05505","article-title":"Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis","volume":"445","author":"Zheng","year":"2007","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.biopha.2023.115611_bib33","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0952-7915(00)00228-4","article-title":"Signaling by type I and II cytokine receptors: ten years after","volume":"13","author":"Gadina","year":"2001","journal-title":"Curr. Opin. Immunol."},{"issue":"3","key":"10.1016\/j.biopha.2023.115611_bib34","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.jaci.2020.10.022","article-title":"The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases","volume":"147","author":"Damsky","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"issue":"4","key":"10.1016\/j.biopha.2023.115611_bib35","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.immuni.2012.03.014","article-title":"JAK and STAT signaling molecules in immunoregulation and immune-mediated disease","volume":"36","author":"O'Shea","year":"2012","journal-title":"Immunity"},{"issue":"10","key":"10.1016\/j.biopha.2023.115611_bib36","doi-asserted-by":"crossref","DOI":"10.1038\/nsmb.2673","article-title":"Structure of a pseudokinase-domain switch that controls oncogenic activation of Jak kinases","volume":"20","author":"Toms","year":"2013","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"12","key":"10.1016\/j.biopha.2023.115611_bib37","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1021\/jm401490p","article-title":"Discovery and development of janus kinase (JAK) inhibitors for inflammatory diseases","volume":"57","author":"Clark","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2023.115611_bib38","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1146\/annurev.immunol.16.1.293","article-title":"Jaks and STATs: biological implications","volume":"16","author":"Leonard","year":"1998","journal-title":"Annu. Rev. Immunol."},{"issue":"8","key":"10.1016\/j.biopha.2023.115611_bib39","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/nri1153","article-title":"Class II cytokine receptors and their ligands: Key antiviral and inflammatory modulators","volume":"3","author":"Renauld","year":"2003","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biopha.2023.115611_bib40","first-page":"12","article-title":"Major role of the IL17\/23 axis in psoriasis supports the development of new targeted therapies","author":"Bugaut","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2023.115611_bib41","first-page":"12","article-title":"Role of Th22 cells in the pathogenesis of autoimmune diseases","author":"Jiang","year":"2021","journal-title":"Front. Immunol."},{"issue":"20","key":"10.1016\/j.biopha.2023.115611_bib42","doi-asserted-by":"crossref","first-page":"8973","DOI":"10.1021\/acs.jmedchem.9b00444","article-title":"Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165","volume":"62","author":"Wrobleski","year":"2019","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.biopha.2023.115611_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2021.11.001","article-title":"Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis","volume":"149","author":"Catlett","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.biopha.2023.115611_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106642","article-title":"Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis","volume":"189","author":"Roskoski","year":"2023","journal-title":"Pharmacol. Res."},{"issue":"10","key":"10.1016\/j.biopha.2023.115611_bib45","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1038\/jid.2010.165","article-title":"A subpopulation of CD163-positive macrophages is classically activated in psoriasis","volume":"130","author":"Fuentes-Duculan","year":"2010","journal-title":"J. Investig. Dermatol."},{"issue":"3","key":"10.1016\/j.biopha.2023.115611_bib46","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/S0002-9394(03)00322-2","article-title":"Evaluation of hematoxylin and eosin and special stains for the detection of acanthamoeba keratitis in penetrating keratoplasties","volume":"136","author":"Grossniklaus","year":"2003","journal-title":"Am. J. Ophthalmol."},{"issue":"3","key":"10.1016\/j.biopha.2023.115611_bib47","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1084\/jem.127.3.507","article-title":"Pathogenesis of the glomerulonephritis of NZB\/W mice","volume":"127","author":"Lambert","year":"1968","journal-title":"J. Exp. Med."},{"issue":"7503","key":"10.1016\/j.biopha.2023.115611_bib48","doi-asserted-by":"crossref","DOI":"10.1038\/nature13199","article-title":"Nociceptive sensory neurons drive interleukin-23-mediated psoriasiform skin inflammation","volume":"510","author":"Riol-Blanco","year":"2014","journal-title":"Nature"},{"issue":"35","key":"10.1016\/j.biopha.2023.115611_bib49","doi-asserted-by":"crossref","first-page":"E3669","DOI":"10.1073\/pnas.1405798111","article-title":"Mannan induces ROS-regulated, IL-17A-dependent psoriasis arthritis-like disease in mice","volume":"111","author":"Khmaladze","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.biopha.2023.115611_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00128071-200708010-00001","article-title":"Acquired palmoplantar keratoderma","volume":"8","author":"Patel","year":"2007","journal-title":"Am. J. Clin. Dermatol."},{"issue":"4","key":"10.1016\/j.biopha.2023.115611_bib51","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nrgastro.2015.34","article-title":"Epidemiology and risk factors for IBD","volume":"12","author":"Ananthakrishnan","year":"2015","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.biopha.2023.115611_bib52","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.immuni.2006.05.017","article-title":"Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology","volume":"25","author":"Uhlig","year":"2006","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.biopha.2023.115611_bib53","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1365-2249.2008.03758.x","article-title":"Overexpression of interleukin-12 and T helper 1 predominance in lupus nephritis","volume":"154","author":"Tucci","year":"2008","journal-title":"Clin. Exp. Immunol."},{"issue":"3","key":"10.1016\/j.biopha.2023.115611_bib54","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"New Engl. J. Med."},{"issue":"19","key":"10.1016\/j.biopha.2023.115611_bib55","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"Jama"},{"issue":"10275","key":"10.1016\/j.biopha.2023.115611_bib56","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S0140-6736(21)00184-7","article-title":"Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis","volume":"397","author":"Ghoreschi","year":"2021","journal-title":"Lancet"},{"issue":"10136","key":"10.1016\/j.biopha.2023.115611_bib57","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","article-title":"Psoriatic arthritis 1 The pathogenesis of psoriatic arthritis","volume":"391","author":"Veale","year":"2018","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.biopha.2023.115611_bib58","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.tips.2022.02.008","article-title":"Selective tyrosine kinase 2 inhibitors in inflammatory bowel disease","volume":"43","author":"Nielsen","year":"2022","journal-title":"Trends Pharmacol. Sci."},{"issue":"4","key":"10.1016\/j.biopha.2023.115611_bib59","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/13543776.2022.2026927","article-title":"Selective TYK2 inhibitors as potential therapeutic agents: a patent review (2019-2021)","volume":"32","author":"de Turiso","year":"2022","journal-title":"Expert Opin. Ther. Pat."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223014099?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223014099?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T21:29:38Z","timestamp":1776461378000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332223014099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":59,"alternative-id":["S0753332223014099"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115611","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of WD-890: A novel allosteric TYK2 inhibitor for the treatment of multiple autoimmune diseases","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115611","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"115611"}}